{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:56:38Z","timestamp":1781636198567,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018778","name":"Al-Azhar University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018778","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The entry of the hepatitis C virus (HCV) into liver cells is closely associated with its interaction with the low-density lipoprotein receptor (LDL-R), which plays a crucial role in facilitating viral uptake. This study aimed to investigate the association between the LDL-R (exon 8\u00a0C.1171 G\/A) gene polymorphism and response to antiviral therapy in patients infected with HCV. Participants were divided into three groups. Group I included 30 patients positive for both anti-HCV antibodies and HCV-RNA who did not respond to antiviral therapy. Group II consisted of 60 patients positive for anti-HCV but negative for HCV-RNA, indicating successful treatment response. and Group III comprised 50 healthy individuals negative for both anti-HCV antibodies and HCV-RNA, serving as controls. Diagnostic assessments included reverse transcriptase-polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), and standard biochemical tests. Genotyping for LDL-R (exon 8\u00a0C.1171 G\/A) polymorphisms was conducted using allele-specific PCR on patients from both the responder and non-responder groups. Of the 376 infected patients receiving antiviral therapy, 345 (91.8%) exhibited a positive response to treatment, whereas 31 (8.2%) did not. A total of 90 patients (60 responders and 30 non-responders) were included for genotypic analysis. Among responders, the A\/A genotype of LDL-R (exon 8\u00a0C.1171 G\u2009&gt;\u2009A) was the most prevalent (61.7%), whereas the G\/G genotype was predominant among non-responders (76.7%). Genotyping analysis demonstrated that hepatitis C virus genotype 4 was the most common, being detected in all 20 responders and in 10 of 20 non-responders. These findings indicate a significant association between LDL-R (exon 8\u00a0C.1171 G\/A) genetic variants and the response to antiviral therapy in Egyptian patients with chronic hepatitis C.<\/jats:p>","DOI":"10.1038\/s41598-026-38468-w","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:33:05Z","timestamp":1771637585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between LDL-R (exon 8\u00a0C.1171 G\u2009&gt;\u2009A) polymorphisms and response to antiviral therapy in hepatitis C virus infection"],"prefix":"10.1038","volume":"16","author":[{"given":"Mohey Eldin Hassan","family":"Shikhoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham A. M.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Abdou O.","family":"Abeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"38468_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah, K., Groeger, J., Flaxman, A. D. & Wiersma, S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV Seroprevalence. Hepatology 57, 1333\u20131342 (2013).","journal-title":"Hepatology"},{"key":"38468_CR2","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","volume":"385","author":"DP Webster","year":"2015","unstructured":"Webster, D. P., Klenerman, P. & Dusheiko, G. M. Hepatitis C. Lancet 385, 1124\u20131135 (2015).","journal-title":"Lancet"},{"key":"38468_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2023.10.015","volume":"80","author":"V Ratziu","year":"2024","unstructured":"Ratziu, V. et al. Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions. J. Hepatol. 80, 335\u2013351 (2024).","journal-title":"J. Hepatol."},{"key":"38468_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/hep.21321","volume":"44","author":"H Barth","year":"2006","unstructured":"Barth, H., Liang, J. T. & Baumert, T. F. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 44, 527\u2013535 (2006).","journal-title":"Hepatology"},{"key":"38468_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/biomedicines11020271","volume":"11","author":"W Elgretli","year":"2023","unstructured":"Elgretli, W., Chen, T., Kronfli, N. & Sebastiani, G. Hepatitis C Virus-Lipid interplay: pathogenesis and clinical impact. Biomedicines 11, 271 (2023).","journal-title":"Biomedicines"},{"key":"38468_CR6","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1365-2893.2011.01576.x","volume":"19","author":"J Guerra","year":"2012","unstructured":"Guerra, J., Garenne, M., Mohamed, M. K. & Fontanet, A. HCV burden of infection in egypt: results from a nationwide survey. J. Viral Hepatitis. 19, 560\u2013567 (2012).","journal-title":"J. Viral Hepatitis"},{"key":"38468_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s43066-022-00232-w","volume":"12","author":"F Butt","year":"2022","unstructured":"Butt, F. et al. A review on hepatitis C virus: role of viral and host-cellular factors in replication and existing therapeutic strategies. Egypt. Liver J. 12, 71 (2022).","journal-title":"Egypt. Liver J."},{"key":"38468_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1743-422X-9-30","volume":"9","author":"B Sainz","year":"2012","unstructured":"Sainz, B., Barretto, N., Yu, X., Corcoran, P. & Uprichard, S. L. Permissiveness of human hepatoma cell lines for HCV infection. Virol. J. 9, 30 (2012).","journal-title":"Virol. J."},{"key":"38468_CR9","doi-asserted-by":"publisher","first-page":"e0303265","DOI":"10.1371\/journal.pone.0303265","volume":"19","author":"Y Pewkliang","year":"2024","unstructured":"Pewkliang, Y. et al. Immortalized hepatocyte-like cells: A competent hepatocyte model for studying clinical HCV isolate infection. PLOS ONE. 19, e0303265 (2024).","journal-title":"PLOS ONE"},{"key":"38468_CR10","doi-asserted-by":"crossref","unstructured":"Ishibashi, M. et al. CLEC4M-positive and CD81-negative Huh7 cells are not susceptible to JFH-1 HCVcc infection but mediate transinfection. Arch. Virol. ;159, 2949\u20132955 (2014).","DOI":"10.1007\/s00705-014-2150-z"},{"key":"38468_CR11","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.3390\/ijms21062091","volume":"21","author":"C Colpitts","year":"2020","unstructured":"Colpitts, C., Tsai, P-L. & Zeisel, M. Hepatitis C virus entry: an intriguingly complex and highly regulated process. Int. J. Mol. Sci. 21, 2091 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"38468_CR12","doi-asserted-by":"publisher","first-page":"e1007111","DOI":"10.1371\/journal.ppat.1007111","volume":"14","author":"J Bruening","year":"2018","unstructured":"Bruening, J. et al. Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB. PLoS Pathog. 14, e1007111 (2018).","journal-title":"PLoS Pathog."},{"key":"38468_CR13","doi-asserted-by":"publisher","first-page":"119082","DOI":"10.1016\/j.atherosclerosis.2024.119082","volume":"401","author":"K Ndoj","year":"2025","unstructured":"Ndoj, K., Meurs, A., Papaioannou, D., Bjune, K. & Zelcer, N. The low-density lipoprotein receptor: emerging post-transcriptional regulatory mechanisms. Atherosclerosis 401, 119082 (2025).","journal-title":"Atherosclerosis"},{"key":"38468_CR14","doi-asserted-by":"crossref","unstructured":"Islam, M. M., Tamlander, M., Hlushchenko, I., Ripatti, S. & Pfisterer, S. G. Large-Scale Functional Characterization of Low-Density Lipoprotein Receptor Gene Variants Improves Risk Assessment in Cardiovascular Disease. JACC: Basic to Translational Science;10:170\u201383. (2025).","DOI":"10.1016\/j.jacbts.2024.10.006"},{"key":"38468_CR15","doi-asserted-by":"publisher","first-page":"e1006905","DOI":"10.1371\/journal.pcbi.1006905","volume":"15","author":"M Kalemera","year":"2019","unstructured":"Kalemera, M., Mincheva, D., Grove, J. & Illingworth, C. J. R. Building a mechanistic mathematical model of hepatitis C virus entry. PLoS Comput. Biol. 15, e1006905 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"38468_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.antiviral.2014.01.004","volume":"104","author":"E Ogawa","year":"2024","unstructured":"Ogawa, E. et al. Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection. Antiviral Res. 104, 102\u2013109 (2024).","journal-title":"Antiviral Res."},{"key":"38468_CR17","doi-asserted-by":"publisher","first-page":"107849","DOI":"10.1016\/j.jbc.2024.107849","volume":"300","author":"F-L Cosset","year":"2024","unstructured":"Cosset, F-L. & Denolly, S. Lipoprotein receptors: A little grease for enveloped viruses to open the lock? J. Biol. Chem. 300, 107849 (2024).","journal-title":"J. Biol. Chem."},{"key":"38468_CR18","doi-asserted-by":"publisher","first-page":"101457","DOI":"10.1016\/j.aohep.2024.101457","volume":"29","author":"L Campos-Medina","year":"2024","unstructured":"Campos-Medina, L., Panduro, A., Gonzalez-Aldaco, K., Laguna-Meraz, S. & Roman, S. Hepatitis C virus-infected patients carriers of the TT (C*52T, rs14158) genotype of the LDL receptor and Apo3 present severe liver damage in West Mexico. Ann. Hepatol. 29, 101457 (2024).","journal-title":"Ann. Hepatol."},{"key":"38468_CR19","doi-asserted-by":"crossref","unstructured":"Gomaa, A., Gomaa, M., Allam, N. & Waked, I. Hepatitis C Elimination in Egypt: Story of Success. Pathogens;13:681. (2024).","DOI":"10.3390\/pathogens13080681"},{"key":"38468_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S2468-1253(24)00442-4","volume":"10","author":"A Artenie","year":"2025","unstructured":"Artenie, A. et al. Global, regional, and National estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis. Lancet Gastroenterol. Hepatol. 10, 315\u2013331 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"38468_CR21","doi-asserted-by":"crossref","unstructured":"Asim, M. IL28B rs12979860 gene polymorphism and sofosbuvir-based therapy response in HCV-infected Pakistani patients. Int. J. Med. Biochem. 7, 73\u201380. (2024).","DOI":"10.14744\/ijmb.2024.75437"},{"key":"38468_CR22","doi-asserted-by":"publisher","first-page":"106258","DOI":"10.1016\/j.jinf.2024.106258","volume":"89","author":"TR O\u2019Brien","year":"2024","unstructured":"O\u2019Brien, T. R. et al. IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C. J. Infect. 89, 106258 (2024).","journal-title":"J. Infect."},{"key":"38468_CR23","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jceh.2021.11.004","volume":"12","author":"P Sharma","year":"2022","unstructured":"Sharma, P. Value of liver function tests in cirrhosis. J. Clin. Experimental Hepatol. 12, 948\u2013964 (2022).","journal-title":"J. Clin. Experimental Hepatol."},{"key":"38468_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.aohep.2019.08.004","volume":"19","author":"D Iluz-Freundlich","year":"2020","unstructured":"Iluz-Freundlich, D., Zhang, M., Uhanova, J. & Minuk, G. Y. The relative expression of hepatocellular and cholestatic liver enzymes in adult patients with liver disease. Ann. Hepatol. 19, 204\u2013208 (2020).","journal-title":"Ann. Hepatol."},{"key":"38468_CR25","doi-asserted-by":"crossref","unstructured":"Badawi, R. et al. Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients with Chronic Hepatitis C: Real-world Results from 1716 Patients in Egypt. Endocrine, Metabolic & Immune Disorders - Drug Targets;19:1005\u201311. (2019).","DOI":"10.2174\/1871530319666190204154830"},{"key":"38468_CR26","first-page":"681","volume":"7","author":"MEH Shikhoun","year":"2024","unstructured":"Shikhoun, M. E. H. & Farghaly, O. A. M. The study of Alpha-Fetoprotein (AFP) levels before and after treatment of hepatitis C virus in Egyptian patients. SVU-International J. Med. Sci. 7, 681\u2013693 (2024).","journal-title":"SVU-International J. Med. Sci."},{"key":"38468_CR27","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/S1665-2681(19)31965-9","volume":"5","author":"B de Olaechea","year":"2006","unstructured":"de Olaechea, B. Predictive factors for response to treatment of chronic hepatitis C. Ann. Hepatol. 5, S24\u2013S28 (2006).","journal-title":"Ann. Hepatol."},{"key":"38468_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s43066-023-00247-x","volume":"13","author":"MS Marie","year":"2023","unstructured":"Marie, M. S. et al. Prediction of hepatic decompensation and hepatocellular carcinoma after direct-acting antiviral therapy in patients with hepatitis C-related liver cirrhosis: a cohort study. Egypt. Liver J. 13, 12 (2023).","journal-title":"Egypt. Liver J."},{"key":"38468_CR29","doi-asserted-by":"crossref","unstructured":"Corma-G\u00f3mez, A. et al. FibroScan-AST score vs liver stiffness for the prediction of liver events after HCV cure. Open Forum Infect. Dis. 12, ofae628 (2025).","DOI":"10.1093\/ofid\/ofae628"},{"key":"38468_CR30","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1002\/hep4.2098","volume":"6","author":"T Huynh","year":"2022","unstructured":"Huynh, T., Ma, S. & Hu, K. HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30\/19 criteria and improved APRI and FIB-4 scores. Hepatol. Commun. 6, 3496\u20133504 (2022).","journal-title":"Hepatol. Commun."},{"key":"38468_CR31","doi-asserted-by":"crossref","unstructured":"Marsh, T. L. et al. HCC surveillance in hepatitis C: A longitudinal algorithm improves alpha-fetoprotein screening. Hepatol. Commun. 9, e0719 (2025).","DOI":"10.1097\/HC9.0000000000000719"},{"key":"38468_CR32","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3855\/jidc.18410","volume":"18","author":"S Sargsyan","year":"2024","unstructured":"Sargsyan, S. et al. Evaluation of the risk of developing hepatocellular carcinoma in chronic hepatitis C patients receiving antiviral treatment. J. Infect. Developing Ctries. 18, 794\u2013801 (2024).","journal-title":"J. Infect. Developing Ctries."},{"key":"38468_CR33","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1002\/hep4.2015","volume":"6","author":"F Tacke","year":"2022","unstructured":"Tacke, F. et al. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: data from the German hepatitis C-Registry. Hepatol. Commun. 6, 2488\u20132495 (2022).","journal-title":"Hepatol. Commun."},{"key":"38468_CR34","doi-asserted-by":"crossref","unstructured":"Everhart, J. E. & Wright, E. C. Association of \u03b3-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology; 57:1725\u201333. (2013).","DOI":"10.1002\/hep.26203"},{"key":"38468_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12876-023-03099-2","volume":"24","author":"VYS Chow","year":"2024","unstructured":"Chow, V. Y. S. & Cheung, W. I. Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong. BMC Gastroenterol. 24, 49 (2024).","journal-title":"BMC Gastroenterol."},{"key":"38468_CR36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s12885-021-08401-7","volume":"21","author":"T Watanabe","year":"2021","unstructured":"Watanabe, T. et al. AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy. BMC Cancer. 21, 699 (2021).","journal-title":"BMC Cancer"},{"key":"38468_CR37","doi-asserted-by":"publisher","first-page":"11141","DOI":"10.3748\/wjg.v21.i39.11141","volume":"21","author":"M Naga","year":"2015","unstructured":"Naga, M. Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response. World J. Gastroenterol. 21, 11141 (2015).","journal-title":"World J. Gastroenterol."},{"key":"38468_CR38","unstructured":"Radera, S., Rungta, S., Jeet, S., Jain, A. & A Sustained Virological Response after Direct-Acting Antiviral Therapy in Hepatitis C Virus-Infected Individuals with and without Decompensated Liver Cirrhosis (A One-Year Follow-Up Study, 2025)."},{"key":"38468_CR39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/pathogens13010068","volume":"13","author":"CJ Fernandez","year":"2024","unstructured":"Fernandez, C. J., Alkhalifah, M., Afsar, H. & Pappachan, J. M. Metabolic Dysfunction-Associated fatty liver disease and chronic viral hepatitis: the interlink. Pathogens 13, 68 (2024).","journal-title":"Pathogens"},{"key":"38468_CR40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jhep.2022.01.029","volume":"77","author":"J Leslie","year":"2022","unstructured":"Leslie, J., Geh, D., Elsharkawy, A. M., Mann, D. A. & Vacca, M. Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions. J. Hepatol. 77, 219\u2013236 (2022).","journal-title":"J. Hepatol."},{"key":"38468_CR41","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2017.01.041","volume":"152","author":"K Matsuura","year":"2017","unstructured":"Matsuura, K. et al. Genome-Wide association study identifies TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus infection. Gastroenterology 152, 1383\u20131394 (2017).","journal-title":"Gastroenterology"},{"key":"38468_CR42","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/hep.28473","volume":"63","author":"V Leroy","year":"2016","unstructured":"Leroy, V. et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 63, 1430\u20131441 (2016).","journal-title":"Hepatology"},{"key":"38468_CR43","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.3390\/v4123281","volume":"4","author":"M Rau","year":"2012","unstructured":"Rau, M., Baur, K. & Geier, A. Host genetic variants in the pathogenesis of hepatitis C. Viruses 4, 3281\u20133302 (2012).","journal-title":"Viruses"},{"key":"38468_CR44","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/QAD.0b013e3283528b1c","volume":"26","author":"A Rivero-Juarez","year":"2012","unstructured":"Rivero-Juarez, A. et al. LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN\/RBV in HIV\/HCV patients. AIDS 26, 1009\u20131015 (2012).","journal-title":"AIDS"},{"key":"38468_CR45","doi-asserted-by":"crossref","unstructured":"Fairoozy, R. H., White, J., Palmen, J., Kalea, A. Z. & Humphries, S. E. Identification of the Functional Variant(s) that Explain the Low-Density Lipoprotein Receptor (LDLR) GWAS SNP rs6511720 Association with Lower LDL-C and Risk of CHD Vol. 11, e0167676 (PLOS ONE, 2016).","DOI":"10.1371\/journal.pone.0167676"},{"key":"38468_CR46","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/jmv.20693","volume":"78","author":"H Li","year":"2006","unstructured":"Li, H., Liu, Z., Han, Q., Li, Y. & Chen, J. Association of genetic polymorphism of low-density lipoprotein receptor with chronic viral hepatitis C infection in Han Chinese. J. Med. Virol. 78, 1289\u20131295 (2006).","journal-title":"J. Med. Virol."},{"key":"38468_CR47","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/hep.29693","volume":"67","author":"PR Harrington","year":"2018","unstructured":"Harrington, P. R. et al. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: regulatory analyses and perspectives. Hepatology 67, 2430\u20132448 (2018).","journal-title":"Hepatology"},{"key":"38468_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/ID9.0000000000000137","volume":"4","author":"NA Makhlouf","year":"2024","unstructured":"Makhlouf, N. A., Abu-Elfatth, A., Khaled, T. & El-Kassas, M. The interplay between schistosomiasis and hepatitis C virus: battling on two fronts. Infect. Dis. Immun. 4, 187\u2013193 (2024).","journal-title":"Infect. Dis. Immun."},{"key":"38468_CR49","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1086\/315786","volume":"182","author":"SC Ray","year":"2000","unstructured":"Ray, S. C., Arthur, R. R., Carella, A., Bukh, J. & Thomas, D. L. Genetic epidemiology of hepatitis C virus throughout Egypt. J. Infect. Dis. 182, 698\u2013707 (2000).","journal-title":"J. Infect. Dis."},{"key":"38468_CR50","doi-asserted-by":"crossref","unstructured":"Boukaira, S. et al. Hepatitis C in North Africa: A Comprehensive Review of Epidemiology, Genotypic Diversity, and Hepatocellular Carcinoma (Advances in Virology, 2025).","DOI":"10.1155\/av\/9927410"},{"key":"38468_CR51","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1128\/JCM.02366-06","volume":"45","author":"DG Murphy","year":"2007","unstructured":"Murphy, D. G. et al. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C\/E1 and 5\u2032 UTR regions. J. Clin. Microbiol. 45, 1102\u20131112 (2007).","journal-title":"J. Clin. Microbiol."},{"issue":"6","key":"38468_CR52","first-page":"1828","volume":"54","author":"E Blanchard","year":"2011","unstructured":"Blanchard, E., Belouzard, S., Goueslain, L., Wielgoszewska, K. & Dubuisson, J. Role of low\u2013density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 54 (6), 1828\u20131837 (2011).","journal-title":"Hepatology"},{"issue":"9","key":"38468_CR53","first-page":"1340","volume":"13","author":"EA Mohamad","year":"2020","unstructured":"Mohamad, E. A., Ahmed, M., El-Kafrawy, S. & Hassan, W. Seroprevalence of HCV infection among individuals attending health check\u2010ups in upper egypt: implications for surveillance and early diagnosis. J. Infect. Public. Health. 13 (9), 1340\u20131347 (2020).","journal-title":"J. Infect. Public. Health"},{"key":"38468_CR54","first-page":"1","volume":"11","author":"A Elsharkawy","year":"2019","unstructured":"Elsharkawy, A., El-Karaksy, H., Kotb, S., Gomaa, A. & Waked, I. Hepatitis C in egypt: Prevalence, impact and management strategies. Hepat. Med. 11, 1\u201310 (2019).","journal-title":"Hepat. Med."},{"issue":"3","key":"38468_CR55","first-page":"1491","volume":"93","author":"MM Hassan","year":"2021","unstructured":"Hassan, M. M. et al. Host genetic factors influencing response to direct-acting antivirals in Egyptian patients with chronic HCV infection. J. Med. Virol. 93 (3), 1491\u20131500 (2021).","journal-title":"J. Med. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38468-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38468-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38468-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:35:25Z","timestamp":1781634925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38468-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38468"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38468-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"7473"}}